Tumor microenvironment is composed of different cell types including immune cells. Far from acting to eradicate cancer cells, these bone marrow-derived components could be involved in carcinogenesis and/or tumor invasion and metastasis. Here, we describe an alternative approach to treat solid tumors based on the genetic modification of hematopoietic stem and progenitor cells with lentiviral vectors. To achieve transgene expression in derivative tumor infiltrating leukocytes and to try to decrease systemic toxicity, we used the stress inducible human HSP70B promoter. Functionality of the promoter was characterized in vitro using hyperthermia. Antitumor efficacy was assessed by ex vivo genetic modification of lineage-negative cells with lentiviral vectors encoding the dominant-negative mutant of the human transforming growth factor-b receptor II (TbRIIDN) driven by the HSP70B promoter, and reinfusion of cells into recipient mice. Subsequently, syngeneic GL261 glioma cells were subcutaneously injected into bone marrow-transplanted mice. As a result, a massive antitumor response was observed in mice harboring TbRIIDN under the HSP70B promoter, without the need of any external source of stress. In summary, this study shows that stem cell-based gene therapy in combination with spatial and temporal control of transgene expression in derivative tumor-infiltrating cells represents an alternative strategy for the development of novel antitumor therapies.
INTRODUCTION
The infiltration of tumors by inflammatory cells encompasses numerous leukocyte subsets, including macrophages, dendritic cells and T cells. Although the immune system recognizes malign formations and starts antigen-specific responses, the overall response is completely inadequate. 1 Therefore, genetic modification of hematopoietic stem and progenitor cell (HSPC) to express anticancer transgenes in derivative tumor-infiltrating cells could represent an attractive avenue for the treatment of solid tumors.
The mechanism of tumor-mediated immunosuppression has been controversially discussed. It has been proposed that either tumor-infiltrating leukocytes die because of activation-induced cell death 2 or that cancer cells escape the immune response by expressing several immunosuppressive cytokines. 3 The concept of altering the local immune microenvironment with cytokines to enhance the immune response, or at least, to bypass the cancer-mediated immunosuppressive effects has been an attractive strategy in cancer gene therapy. However, in spite of successful local application of potent therapeutic cytokines by gene therapy in animal models, 4, 5 cancer clinical trials have shown severe side effects in treated patients. 6, 7 Several strategies, with varying degree of success, have been employed to decrease unwanted secondary effects, in which gene expression could be induced with physical 8 or biochemical 9 systems or through diseasespecific gene activation. 10, 11 Receptor-mediated blockade of transforming growth factor (TGF)-b signaling in bone marrow (BM) cells by retroviral-mediated gene therapy in mice using a dominant-negative mutant of TGF-b receptor II (TbRIIDN) has already been used efficiently to suppress tumor metastasis. 12 This dominant-negative receptor is capable to bind all three TGF-b isoforms, without mediating signal transduction. But, it has been reported that, a systemic expression of this receptor led to generate a phenotype similar to that of TGF-b À/À mice with multiorgan inflammation and the production of autoantibodies. 13 The survival rate of transplanted mice drastically decreased while expressing TbRIIDN.
14 This lack of functional TGF-b signaling in the myeloid compartment of adult mice may trigger suppression of lymphocytes that would otherwise proliferate when rendered insensitive to TGF-b.
14 This emphasizes the need of a strong controllable gene expression system in cancer gene therapy avoiding cellular dysfunctions and systemic toxicity.
Heat-shock promoters (HSP) have been often used for gene therapy strategies owing to their efficiency to induce spatial and temporal gene expression. Particularly, versions of the human HSP70B promoter have been widely used for the expression of therapeutic genes in replication-defective adenoviral vectors 15, 16 by applying hyperthermia. 17 --19 However, the influence of stresses present in the tumor microenvironment on the HSP70B activation in tumor-infiltrating leukocytes have never been reported.
In this study, taking advantage of the tumor infiltrative nature of BM-derived inflammatory cells and the stress occurring in the tumor microenvironment, we developed a hematopoietic stem cell-based cancer gene therapy approach to treat solid tumors. We first designed a lentiviral inducible expression system based on the human HSP70B promoter and characterized its regulatory potential by using hyperthermia in human and mice cell lines. We next analyzed, in vivo, the capacity of the promoter to drive gene expression in tumor-infiltrating leukocytes after bone marrow transplantation (BMT) of genetically modified HSPC. Finally, we studied the preventive therapeutic approach of this inducible lentiviral expression system in a local cytokine-based anticancer therapy, using TbRIIDN.
Here we provide proof-of-principle evidence that stem cell-based gene therapy combined with stress inducible gene expression could be an alternative strategy to overexpress therapeutic transgenes in the tumor microenvironment.
MATERIALS AND METHODS

Viral constructs
Transfer vectors were generated by cloning either the human HSP70B promoter or the cytomegalovirus (CMV) immediate early promoter upstream the enhanced green fluorescence protein (EGFP) complementary DNA or the TbRIIDN, in the self-inactivating-lentiviral vector plasmid pRRLSin18-cPPT-EGFP-wpre (kindly provided by Luigi Naldini, Milan, Italy). Additionally, a selectable cassette containing either the neomycin resistance gene (neo R ) or EGFP driven by the phosphoglycerate kinase (PGK) promoter was included. The resulting vectors were named CMV/EGFP (pRRL-Sin18-CMV.EGFP-PGK.neo R ), HSP/EGFP (pRRL-Sin18-Hsp70B.EGFP-PGK.neo R ) (Figure 1a ), promoterless control (pRRL-Sin18-EGFP-PGK.neo R ) (Figure 1b) , CMV/TbRIIDN (pRRL-Sin18-CMV.TbRIIDN-PGK.EGFP), HSP/ TbRIIDN (pRRL-Sin18-HSP70B.TbRIIDN-PGK.EGFP) ( Figure 1c ) and vector control (pRRL-Sin18-PGK.EGFP) (Figure 1d ).
Lentiviral cell-free supernatants were generated by transient cotransfection of 293T packaging cells with each transfer vectors together with the packaging plasmid pMDL-gp-rre, the rev-expressing plasmid pRSV-rev and the VSV-g-expressing plasmid, as previously described. 20 Viral titers were determined on A549 cells in the presence of 1 mg ml ) cells from donor C57BL/6 mice were isolated from complete BM by magnetic sorting using the Lineage Cell Depletion Kit (Miltenyi Biotech, Bergisch-Gladbach, Germany), following the instructions given by the manufacturer. Briefly, total BM cells were magnetically labelled with a cocktail of biotinylated antibodies against a panel of lineage antigens (CD3, B220, CD11b, Gr-1 and Ter-119) and antibiotin MicroBeads (Miltenyi Biotech). Lin À cells were automatically separated using an AutoMACS device (Miltenyi Biotech), and grown in StemSpan HS2000 medium (CellSystems, St Katharinen, Germany) supplemented with 100 U ml À1 pen/strep, 2 mM glutamine, 50 ng ml À1 murine stem cell factor, 100 ng ml À1 hFlt-3 ligand, 100 ng ml À1 human interleukin-11 and 10 ng ml À1 mouse interleukin-3 (PeproTech, London, UK) at a density of 10 5 cells per ml. All cell lines and primary cultures were grown at 37 1C in a CO 2 incubator, unless otherwise specified.
Lentiviral transduction Lin
À cells were expanded for 3 days before transduction. On day 4, cells were transduced by spinocculation during 60 min, at 700 Â g and room temperature, in the presence of 8 mg ml À1 polybrene at a multiplicity of infection of 10. Transduced cells were expanded for 72 h, before proceeding with further experiments.
BMT Recipient C57BL/6 mice (n ¼ 6) were irradiated in ventilated Plexiglas (Evonik Industries AG, Darmstadt, Germany) containers using a b-emitter lineal accelerator device (Siemens, Erlangen, Germany). Total body irradiation was given as a single exposure of 10 Gy at a dose rate of 0.5 Gy min À1 . Four hours later, each mouse received 400 ml sterile phosphate-buffered saline containing 1 Â 10 6 Lin À intravenously. Transplanted mice were maintained under Ciprofloxacin (Bayer Vital GmbH, Wuppertal, Germany)-supplemented water for 3 weeks.
Achieved chimerism was determined by flow cytometry analysis of EGFP expressing peripheral blood CD4 + lymphocytes (Supplementary Figure 1) .
Generation and measurement of glioma
Gliomas were generated by subcutaneous injection of 4 Â 10 5 syngeneic GL261 cells per mouse, 21 days after BMT. The diameter of the tumors was established every second day by measuring tumor perimeter with a digital caliper. Mean tumor volume was calculated following the formula V ¼ 4/3 (p x r 3 ). Thirty-two days after implantation of glioma cells, mice were killed by cervical dislocation, and spleen and tumor were kept for further analysis.
Induction and detection of EGFP expression in tumor-bearing BMT mice
Twenty-one days after GL261 injection, tumors and spleens were dissected and single-cell suspensions were obtained by mincing the organs through a 0.7-mm mesh. Erythrocytes were depleted by treatment with red blood cells lysis buffer. Subsequently, two 100-mm plates were seeded with 5 Â 10 6 cells in RPMI medium supplemented with 10% fetal calf serum, 1%
L-glutamine, 1% pen/strep and 1% b-mercaptoethanol. One plate was kept at 37 1C and the other one was incubated at 43 1C for 90 min, to induce gene expression ex vivo. Finally, plates were incubated for a further period of 24 h at 37 1C. EGFP expression in different subpopulation of leukocytes was detected by flow cytometry after incubation with the following Figure 1 . Design of lentiviral vectors used in this study. The cytomegalovirus (CMV) and the HSP70B promoters were used to drive expression of either the enhanced green fluorescence protein (EGFP) (a) or a dominant-negative mutant of TGF-b receptor II (TbRIIDN) (c). Additionally, to allow viral titration, neo R (a and b) and EGFP (c) were included in a separate cassette under the action of the phosphoglycerate kinase (PGK) promoter. Additionally, we used as controls a lentiviral vector containing the EGFP transgene and no promoter (promoterless control) (b) and another, encoding only the EGFP protein under the action of the PGK promoter (vector control) (d). Unless specified, all vectors include the woodchuck hepatitis virus post-transcriptional regulatory element (PRE), a splice donor (SD) and acceptor (SA) sequences, the primer-binding site (y), the rev responsive element (RRE), the central polypurine track (cPPT) and a packaging signal (C).
RESULTS
Characterization of the human HSP70B promoter to control lentivirus-mediated gene expression in mammalian cells
To establish the conditions necessary to induce HSP70B-driven transgene expression, A549
HSP and GL261 HSP cell lines were incubated for 60 min at different temperatures ranging from 39 1C to 43 1C (Figure 2 
To determine the time of induction necessary to achieve optimal HSP70B promoter activity, GL261
HSP and A549 HSP cell lines were kept at 43 1C, and EGFP expression was measured by flow cytometry at different time points, ranging from 0 to 90 min. In both cell lines, EGFP expression became evident after 30 min, and reached maximum levels after 60 min at 43 1C (Figures 3a  and b) . Importantly, transgene expression remained stable even at higher time points without compromising cell viability, as determined by propidium iodide incorporation (Figures 3c and d) . These findings indicate that incubation at 43 1C for 60 min is required to optimally induce the human HSP70B promoter in mammalian cancer cells in vitro. To further characterize the system, we induced gene expression at 43 1C for 60 min and analyzed EGFP expression at different time points after induction (Figure 4) . In both cell lines, maximum levels of gene expression were obtained 6 h after induction. EGFP fluorescence was detectable for at least 4 days at levels obtained with the control cell lines expressing EGFP constitutively (GL261 CMV and A549 CMV ). At day 6, EGFP fluorescence dropped to no induction values, indicating the temporal nature of gene expression. Six days after induction, we could accurately reinduce gene expression by heating the cells at 43 1C for 60 min. Again, maximum levels of gene expression were obtained 6 h after induction, and EGFP fluorescence was evident for an additional 4 days interval, indicating that gene expression can be reinduced without affecting significantly the capacity of the system to be switched on and off.
Lentiviral-mediated HSP70B promoter gene induction in leukocytes of BMT recipient tumor-bearing mice To assess HSP70B-driven gene expression in tumor-infiltrating leukocytes, we ex vivo transduced C57BL/6 Lin À cells either with HSP/EGFP or the CMV/EGFP vectors. Cells were reinfused into lethally irradiated syngeneic recipient mice and 3 weeks later, transplanted animals were injected with GL261 wild-type cells into the flank. On day 21 after tumor injection, animals were killed, spleens and tumors were removed and single-cell suspensions were obtained. Cells were incubated ex vivo either at 37 1C or 43 1C. EGFP expression was measured, by flow cytometry, in different hematopoietic lineages, defined by the presence of the surface markers B220 þ , CD11b þ , CD11c þ , CD4 þ and CD8 þ , present either in spleens (Figure 5a and b) or tumors (Figure 5c and d) . In spleenic leukocytes incubated at 37 1C from mice transplanted with HSP70B/EGFP-transduced Lin À cells, the percentage of EGFPexpressing cells was as low as the percentage found in animals in which Lin À were transduced with the promoterless vector. This finding indicates that in the absence of hyperthermia, the HSP70B promoter is unable to elicit gene expression in spleenic leukocytes. As expected, when spleen single-cell suspensions from the same mice were incubated at 43 1C, the percentage of EGFP-expressing cells increased three-to four --fold, reaching levels obtained in spleen leukocytes from animals transplanted with CMV/EGFP Lin À cells (Figure 5b ). In contrast, in single-cell suspension of tumors from animals that received HSP/EGFP-transduced Lin À cells (Figure 5c and d) , flow cytometry revealed a dramatic increase of EGFP expression in tumor-infiltrating leukocytes, in the absence of hyperthermia. The presence of gene expression only found in leukocytes-infiltrating tumors but not spleens suggests that the HSP70B promoter could also be induced by stressors present in the tumor microenvironment. Our results indicate that, in leukocytes, the HSP70B promoter could be tightly regulated remaining off in the absence of stress (spleen), or to be activated by local sources of stress present in the tumor.
Antitumor effect of TbRIIDN expressed in HSPC-derived tumorinfiltrating inflammatory cells To investigate whether stem cell-based gene therapy could represent a valid therapeutic strategy to treat solid tumors, we transplanted C57BL/6-recipient mice with Lin À cells previously transduced with HSP/TbRIIDN, CMV/TbRIIDN and control vectors. Three weeks after BMT, recipient animals were injected with GL261 wild-type cells and tumor size measured at 48 h intervals for 32 days ( Figure 6 ). As expected, mice transplanted with the vector control-transduced Lin À cells showed a steady and uncontrollable growth of GL261 cells. However, tumors barely grow in mice transplanted with Lin À cells transduced with HSP/TbRIIDN, in the absence of any external application of stress, suggesting that tumor-infiltrating inflammatory cells harnessed with TbRIIDN under the action of the HSP70B promoter recover their antiumoral activity. These results support our observation that stressors in the tumor microenvironment could be responsible for the activation of the HSP70B promoter with a concomitant TbRIIDN expression, hence, leading to a strong antitumor effect.
DISCUSSION
One of the main challenges of gene therapy is to achieve regulatable transgene expression in a spatial and temporal manner to decrease unwanted side effects. Especially in stem cell-based gene therapy where gene expression ideally should be turn on in derivative effectors cells, but not in more undifferentiated progenitors.
Here, we described a strategy that exploits the homing of leukocytes into the tumor microenvironment to direct gene expression of tumoricidal agents. To allow a restricted temporal and spatial transgene expression in tumor-infiltrating cells, we capitalized the regulatable nature of the human HSP70B promoter. Initially, we confirmed, in cancer cell lines, that the HSP70B promoter was able to induce heat-controlled transgene expression. In a similar way, regulation of the HSP70B promoter, either in vitro 21, 22 or in vivo, 23 --26 has also been achieved by others in cancer cells but not in leukocytes. Additionally, the data presented here gives evidence that, in tumor-infiltrating cells, the HSP70B promoter can also be induced, in vivo, without the application of any external source of stress. The lack of blood supply, hypoxia, glucose depletion, accumulation of lactate and other metabolic byproducts, and low extracellular pH are a signature of the tumor microenvironment. 26, 27 This stresses together with the presence of additional inflammatory co-stimuli, such as tumor necrosis factora, interleukin-1 and small metabolites, 28 may account for the induction of HSP70B-driven gene expression in tumor-infiltrating leukocytes in the absence of external stress. The mechanism underlying this phenomenon remains unknown and must be studied in detail, but we hypothesized that differential sensitivity to stresses between leukocytes present in the tumor microenvironment and tumor cells might explain the absence of similar reports in the literature.
To check the antitumor efficacy of the strategy, we achieved neutralization of TGF-b-mediated signaling in tumor-infiltrating hematopoietic cells using a TbRIIDN under the action of the HSP70B promoter. In this way, we have demonstrated that the inhibition of the TGF-b cascade have mounted an efficacious immune response, sufficient to avoid tumor growth in BMT mice.
Similar stem cell-based cancer gene therapy approaches focused on the genetic modification of either BM-derived mesenchymal stem cells 29, 30 or HPSC 31, 32 have been recently reported. De Palma et al. 31 transplanted mouse BM cells transduced with lentiviral vectors, using the Tie-2 promoter to elicit transgene expression restricted to BM-derived macrophages. In a similar approach, Li et al., 32 also employing lentivectors to genetically modify HSPCs, have been able to degrade tumor stroma under the action of the tetracycline inducible promoter, to allow the existing immune response to become tumor destructive. Alternatively, our stem cell-based cancer gene therapy study exploits the stress-inducible nature of the HSP70B promoter to stimulate the antitumor response of immune effector cells by modulation of strong pleiotropic cytokines such as TGF-b.
In summary, we have shown that hematopoietic stem cell transplantation combined with the regulation of gene expression of HSP70B promoter could represent an alternative option to treat solid tumors.
